The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus

Sponsor
Qingdao Zhixin Health Technology Co., Ltd. (Other)
Overall Status
Unknown status
CT.gov ID
NCT03061851
Collaborator
H & J CRO International, Inc. (Industry)
400
1
2
22.2
18

Study Details

Study Description

Brief Summary

The patients with type 2 diabetes who underwent routine hypoglycemic agents and insulin therapy were evaluated for 48 weeks with maltose software.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: conventional treatment
  • Other: Maltose app
N/A

Detailed Description

This study enrolled 400 patients with type 2 diabetes in five centers in Shandong Province, China. Patients with type 2 diabetes who met the inclusion / exclusion criteria were randomly assigned to the trial group (conventional treatment + maltose app) or the control group (conventional treatment) in a 1: 1 ratio.

The control group: given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

The trial group: the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the researcher according to the patient's condition. The intervention was not done in this study.

Interventions include:
  1. Weekly diabetes-related science articles.

  2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.

  3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.

  4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.

  5. Personalize the development of diet, exercise program.

  6. different insulin and oral hypoglycemic drug medication time to remind.

  7. hypoglycemic drug side effects query.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The enrolled patients will be randomly divided into two groups: the trial group and the control group. The estimated sample size was 200 patients for each group.The enrolled patients will be randomly divided into two groups: the trial group and the control group. The estimated sample size was 200 patients for each group.
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
A Multicenter, Prospective, Randomized, Controlled Clinical Trial of the Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus
Actual Study Start Date :
Jan 25, 2017
Anticipated Primary Completion Date :
Aug 1, 2018
Anticipated Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: conventional treatment

given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

Behavioral: conventional treatment
the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

Experimental: conventional treatment + maltose app

the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.

Behavioral: conventional treatment
the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

Other: Maltose app
Weekly diabetes-related science articles. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online. Personalize the development of diet, exercise program. different insulin and oral hypoglycemic drug medication time to remind. hypoglycemic drug side effects query.

Outcome Measures

Primary Outcome Measures

  1. The proportion of patients with HbA1c <7% after 48 weeks of maltose software intervention [48 weeks]

Secondary Outcome Measures

  1. The changes of HbA1c at baseline, 48 weeks, 36 weeks, 24 weeks and 12 weeks after intervention were compared. [48 weeks, 36 weeks, 24 weeks and 12 weeks.]

  2. The changes of FPG and 2hPG, blood lipids and uric acid in the 48 weeks and 24 weeks after the intervention were compared. [48 weeks and 24 weeks]

  3. The proportion of the different subgroups patients(baseline BMI<24kg/m2, ≥24kg/m2 and ≤28kg/m2 and >28kg/m2; baseline HbA1c≤8%,>8% and ≤10% and >10%) with HbA1c<7% after 48 weeks and 24 weeks of intervention [48 weeks and 24 weeks]

  4. The changes of body weight, waist circumference and hip circumference were compared with baseline at 48 weeks, 36 weeks, 24 weeks and 12 weeks after the intervention. [48 weeks, 36 weeks, 24 weeks and 12 weeks]

  5. The total score of the Morisky compliance questionnaire at baseline, 48 weeks, 36 weeks, 24 weeks, and 12 weeks after intervention was compared with baseline. [48 weeks, 36 weeks, 24 weeks, and 12 weeks]

  6. The total score of self - rating anxiety scale at 48 weeks after intervention was higher than baseline. [48 weeks]

  7. The scores of self - management behavior of patients with diabetes at baseline, 48 weeks, 36 weeks, 24 weeks and 12 weeks after intervention were compared. [48 weeks, 36 weeks, 24 weeks and 12 weeks]

  8. The total score of Kessler's psychological distress scale after 48 weeks of intervention was higher than baseline. [48 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male and female patients diagnosed with type 2 diabetes, age ≥ 18 years and ≤ 65 years;

  2. diagnosis of type 2 diabetes ≥6 months;

  3. The patient signed an informed consent form and agreed to collect the data. The trial group agreed to apply the maltose app during the trial period to study popular science articles, to receive software reminders and to answer questions regularly;

  4. HbA1c≥7.0% in the last one (≤3 months) before enrollment;

  5. be able to use Mobile App;

  6. The mobile phone used by the patient must support maltose App installation.

  7. Receiving regular diabetes education in the hospital.

Exclusion Criteria:
  1. Has participated in any randomized controlled clinical study;

  2. To long-term use of insulin pump as the main treatment of type 2 diabetes;

  3. patients with type 1 diabetes;

  4. pregnant or lactating women;

  5. doctor, alcohol, drug abuse, schizophrenia, severe vision and hearing impaired;

  6. Can not accept software manager;

  7. Other investigators considered it inappropriate to participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Qingdao University Hospital Qingdao Shandong China

Sponsors and Collaborators

  • Qingdao Zhixin Health Technology Co., Ltd.
  • H & J CRO International, Inc.

Investigators

  • Study Director: Jian Wang, Qingdao Zhixin Health Technology Co., Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Qingdao Zhixin Health Technology Co., Ltd.
ClinicalTrials.gov Identifier:
NCT03061851
Other Study ID Numbers:
  • APP20160212
First Posted:
Feb 23, 2017
Last Update Posted:
Feb 23, 2017
Last Verified:
Feb 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2017